Point72 Asia (Singapore) Pte. Ltd. Cytom X Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 87,226 shares of CTMX stock, worth $113,393. This represents 0.05% of its overall portfolio holdings.
Number of Shares
87,226Holding current value
$113,393% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
89Shares Held
43.9MCall Options Held
105KPut Options Held
4.5K-
Bvf Inc San Francisco, CA6.6MShares$8.57 Million0.43% of portfolio
-
Tang Capital Management LLC San Diego, CA6.45MShares$8.39 Million1.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.86MShares$6.31 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$4.61 Million0.17% of portfolio
-
Acadian Asset Management LLC Boston, MA2.69MShares$3.5 Million0.02% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $85.7M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...